
|Articles|May 29, 2012
Sanofi, Novo, Lilly Shape up for Big Insulin Fight
Advertisement
Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.
Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.
Read the full story:
Source: Reuters
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
2
Making the Genetic Models Match the Ancestry of Patient Populations
3
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
4
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
5













































